The effects of anaglipitin, a DPP-4 inhibitor, on blood lipids in type 2 diabetic patients.
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 03 Jul 2019
Price : $35 *
At a glance
- Drugs Anagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms ANGELS
- 26 Jun 2019 Status changed from recruiting to active, no longer recruiting.
- 15 Jul 2014 New trial record